NASDAQ:AMLX
Amylyx Pharmaceuticals, Inc. Stock Company Profile
$1.89
-0.0400 (-2.07%)
At Close: May 09, 2024
Information
43 Thorndike Street
Cambridge MA 02141
617 682 0917
amylyx.com
Industry: Biotechnology
Sector: Healthcare
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
